Physician profile
Aida Bounama
NPI 1336405463
$1,594.79
in general payments reported to CMS, 2019-2025
8 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.82 · 2022: $89.84 · 2023: $781 · 2024: $436 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $438.68 | 2024-2025 | Tepezza |
| Glaukos Corporation | $300.40 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $240.29 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $228.19 | 2022-2023 | Tepezza |
| Biotissue Holdings INC. | $171.57 | 2023 | |
| Oyster Point Pharma, INC. | $170.37 | 2022-2023 | Tyrvaya |
| Carl Zeiss Meditec USA, INC. | $29.47 | 2024 | Iolmaster 700 |
| Allergan, INC. | $15.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aida Bounama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.